Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUWXEB)

Drug Name

QPI-1007 Drug Info

Synonyms

SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Ischemic optic neuropathy	9C40.4	Phase 3	[1]
Non-arteritic anterior ischemic optic neuropathy	9C40.40	Phase 3	[2]
Glaucoma/ocular hypertension	9C61	Phase 2/3	[3]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Caspase 2 messenger RNA (CASP2 mRNA)	TT12VNG	CASP2_HUMAN	Not Available	[4]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT02341560) Phase II/III, Randomized, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION). U.S. National Institutes of Health.
4	Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66.